Beauty Groups Are Buying Targets, Not Ingredients

What is the signal?

Amorepacific invested in the biotech Junevity through its corporate venture arm, Amorepacific Ventures, and separately entered a licensing agreement covering cosmetic applications. Amorepacific will lead development and commercialisation of products resulting from the research, while Junevity continues to develop therapeutic applications of the same technology. The collaboration is described as combining Junevity's RESET platform with Amorepacific's expertise in skin biology, cosmetic development and commercialisation.

The RESET platform uses human disease omics, genetic linkages and machine learning and AI to identify transcription factor targets, and represses those targets with siRNA. The partners aim to find pathways that could move ageing skin gene networks toward a healthier state. Junevity was founded out of research at the University of California, San Francisco in 2023 and has raised more than US$20 million in seed financing, led by Goldcrest Capital and Godfrey Capital.

This is not one company's choice. In August 2026 L’Oréal opened a multi-year research collaboration with the healthy longevity academy at NUS Medicine in Singapore, backed by a new joint lab, examining how skin ageing relates to broader biological ageing, with findings feeding its Longevity Integrative Science programme. Estée Lauder Companies presented sirtuin and exosome research at the 2026 IMCAS World Congress and has previously funded longevity research at the Stanford Center on Longevity. The common shape is a venture stake and a multi-year research agreement rather than an acquisition — buying into the research stage, not into a brand.

Let us set the limits of the reading. No investment amount, specific product or launch date has been disclosed, and there has been no announcement that a candidate has reached testing. The evidence behind transcription factor work comes from cell and in vivo studies and from drug development. A peer-reviewed paper published in January 2026 reported that precise modulation of individual transcription factors can reverse core hallmarks of cellular aging and restore tissue function in vivo, but Junevity's lead candidate, JUN_01, is a therapeutic for type 2 diabetes and obesity. Nothing published shows the same result from a topical cosmetic. The L’Oréal and Estée Lauder items are research collaborations and conference presentations, so they are not product performance figures either. The direction is clear all the same: what the large groups are buying has moved from ingredients to targets and data.

1. What was secured is a target and a right, not an ingredient

Ingredient differentiation has mostly been explained by which raw material went in. Raw materials are bought from suppliers, so the same material shows up in several brands' products a few months apart. This deal sits one step earlier: a platform that finds which target in skin ageing to act on, bundled with the right to use that target in cosmetics.

From a brand's side the consequence splits in two. One is that some materials will never arrive on the open supplier list. The other is that materials explaining a similar mechanism with publicly available chemistry get grouped into one story, which makes that space more crowded. It is worth checking which of the two your line is standing in.

So one more question joins the supplier conversation. Where the question used to be whether a material works, it now has to include how much of it you may use, for how long, and under what conditions. Use restrictions and exclusivity terms cannot be changed once the formula is locked.

• Whether the material carries a use restriction or a territory restriction
• If exclusivity exists, its term and minimum purchase quantity
• Whether the data in the proposal is the supplier's own or a third-party citation
• How many publicly available materials already explain the same mechanism

2. Evidence is usable only when the stage it came from is written beside it

Words like transcription factor and cell reprogramming carry very different weight depending on the study behind them. Cell work asks whether the mechanism holds, animal work whether a response appears in a living system, and a clinical trial whether a dose given to people is safe and effective. The question a cosmetic needs answered is different again: what changes when a finished formula is applied to skin for a defined period.

When evidence is attached to a brief, do not copy only the study title. Write four columns beside it: the subject of the study (cells, animals, people), the route of application (injection, oral, topical), the use concentration, and the duration. Data that leaves those columns blank is hard to use as a development decision, and filling them in separates material you can build on from material that is only background.

The core discipline is not stretching ingredient research into finished-product efficacy. Good results at the raw-material stage meet a lower concentration once in a formula, along with a different pH and solubility environment, interactions with other ingredients, and different conditions for skin penetration. That is why even a large group runs a full product development stage after taking a licence.

• Whether the subject of the study was cells, animals or people
• Whether the route was topical, or injection or oral
• Whether the proposed use level is the level your formula actually holds
• Whether a single study exists on the finished product

3. Do not move a drug developer's sentences into a cosmetic

The fact that the cosmetic licence and the therapeutic development are kept separate in this deal is not merely contract structure. It follows from the fact that the ground a cosmetic may stand on differs from the ground a medicine stands on, even with the same underlying technology. Carry the language of disease, repair and regeneration from the therapeutic side into a cosmetic material description and you are no longer describing a product; you are creating exposure.

In practice this line has to be drawn before the formula. Fix the range of claims you intend to make in one line and the testing needed to support them follows, along with the cost and the time those tests add to the production schedule. Choose the material first and the wording later, and you can end up with the quantity and the packaging already committed while no usable sentence is left.

Narrowing the claim is not purely a loss. A specific sentence written inside the permitted range often lands better with customers than a large sentence outside it. Narrow "what changes" into measurable items and those items become the test design.

4. Where a licence is out of reach, the routine becomes the axis

A platform licence or a multi-year joint research programme is not an option for a project starting at 1,000 units. That does not make this trend irrelevant to a small brand. As the large groups build out the frame of care kept up over time, the standard customers judge a product by shifts from one immediate change to whether they can keep using it.

On that standard, the decisive items are ones you can design with publicly available materials. Decide how many times a day, on which area, and over how long the product is used, then design the volume and the dose per actuation around that usage. A product meant to last six months and one that runs out in a month differ in volume, packaging and price structure even on the same formula.

Adherence is also something you can treat with data. A heavy skin feel, a strong fragrance or tackiness after application breaks a long routine. For a product premised on a long period of use, those items deserve checking before the efficacy data does.

• Whether daily frequency and amount per use are set as numbers
• Whether the target period of use was calculated against the volume
• Whether the dose per actuation matches that amount per use
• Whether the sensory issues that break long use were checked in advance

5. Fix the list of documents you require before the formula is locked

The instrument a brand can actually use in this environment is a list of requirements. Build the list of documents you must receive before choosing a material and a polished pitch and a documented pitch can be compared on the same basis. Without the list, the basis of comparison drops to the quality of the sentences in the proposal.

The list should not hold efficacy data alone. Whether supply will hold, whether the minimum purchase quantity matches your production volume, and whether the ingredient sits on a restricted list in the markets you will sell in belong there with equal weight. It is not rare for the material with the best efficacy data to be blocked by supply or regulation.

Finally, it is better to close this list before the formula is locked. Ask for documents after the formula is fixed and your options narrow to that one material, and a shortfall in the data becomes hard to act on.

• Study design (subject, number, duration) and the use concentration
• Stability in the formula and compatibility with other ingredients
• Supply reliability and minimum purchase quantity
• Ingredient status and use restrictions in the markets you will sell in

The first question for the brief

Instead of writing "a longevity line", narrow it to one sentence that carries the conditions of use. Write something like "a 30 mL serum used in the evening routine for six months or more, supported by one study on the finished product", and the volume, the dose per actuation and the number of tests follow directly from that sentence.

The second thing to write is an evidence table. Put the materials you will use on the left, and on the right the study subject, route of application, use concentration and duration. A material with an empty right-hand side is an explanation, not yet evidence. With that table, changing one material shows you what else changes with it.

The last is the range of claims. Fix the range of sentences you will use in one line before the formula is locked, and the testing behind those sentences enters the schedule and the order quantity together. Settle the material first and choose the wording later, and the quantity and the packaging get fixed while no usable sentence remains.